Home › Finerenone Cuts Deaths in Mid-Stage Trial
 

Keywords :   


Finerenone Cuts Deaths in Mid-Stage Trial

2015-09-01 05:16:57| Chemicals - Topix.net

Promising data from an exploratory phase IIb trial of finerenone , an oral, nonsteroidal mineralocorticoid receptor antagonist , have been presented at the European Society of Cardiology Congress 2015 in London. The ARTS-HF study investigated the effects of different dosages of finerenone compared with eplerenone in patients with worsening chronic heart failure with a reduced ejection fraction as well as type-2 diabetes mellitus and/or chronic kidney disease.

Tags: trial cuts deaths

Category:Chemicals

Latest from this category

All news
28.06Jotun Launches CX-Rated Anticorrosive Powder Coating
28.06RPM to Announce Fiscal 2024 4Q, Year-End Results
28.06Evonik Commissions New Plant for AEROSIL Silicas
28.06BCFs Coatings Ambassador Program Trains Its 50th Ambassador
28.06Global Green Building Alliance Launches Guide to Net Zero
27.06Nippon Paint Marines FASTAR Coating Honored by JCIA
27.06Jeremy Sukola Named VP of Prime Resins
27.06CalPoly Hosts Polymers & Coatings Summer 2024 Short Course
Chemicals »
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »